Hot Investor Profile: New Venture Fund Invests in Early-Stage Therapeutics Companies in North America, Europe, and Israel

15 Aug

A newly established venture fund is currently fundraising for their newest fund and actively pursuing new investment opportunities that they can invest through their new fund. Typical check size is $2-5M, and the firm invests exclusively in therapeutics. The firm focuses on opportunities based in North America, Europe, and Israel. About 20% of their investments to date have been in Europe and Israel, while the rest have been in North America-based companies. 
 
The firm invests exclusively in therapeutics companies, and does not pursue medical devices, diagnostics, or digital health opportunities at this time. Within therapeutics, the firm is most interested in advanced therapeutics including genetic diseases, oncology/immuno-oncology, autoimmune, cardiovascular, ophthalmology, fibrosis, and rare/orphan diseases. The firm is least interested in neurodegenerative, infectious diseases, oligonucleotide, and epigenetic drugs, and does not consider reformulated or repurposed drugs. In terms of stage of development, the firm’s sweet spot is between late pre-clinical stage (after animal data) and Phase II. 
 
The firm seeks to invest in technologies backed by strong IP protection. To date, the firm has mostly led or co-led investment rounds, prefers to take an active stance in their portfolio companies, and requires a board seat. However, the firm is open to co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Leave a comment